PTCT: Sephience’s global PKU launch drives strong adoption, with robust pipeline and disciplined growth
Lesedauer weniger als 1 min
Sephience’s global PKU launch shows rapid adoption and strong patient enthusiasm, driven by its unique clinical profile and support infrastructure. The company is expanding manufacturing, managing pricing, advancing R&D, and maintaining expense discipline. Regulatory engagement and partnerships support growth and future launches.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr